Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 229   

Articles published

SNY 54.97 +0.27 (0.49%)
price chart
Sanofi And Regeneron Announce Positive Results For Cholesterol Drug ...
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc. (REGN) announced over the weekend that their experimental drug Alirocumab significantly cut the level of cholesterol in four trials, indicating that the treatment may prevent heart disease and ...
Related articles »  
Sanofi, Regeneron Take Lead In Cholestrol Drug Race
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc (REGN) are head-to-head with Amgen, Inc. (AMGN) to introduce the world's first PCSK9 inhibitor in the market.
Related articles »  
Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C. Difficile ...
The designation puts Pfizer ahead of Sanofi SA (ADR) (SNY), which is also developing a similar vaccine. While most forms of the disease can be cured with antibiotics, there currently exists no preventive care for this infection.
Related articles »  
Amgen And Sanofi Compete To Launch New Class Of Cholesterol-Fighting Drugs
... of the new generation PCSK9 inhibitors. Amgen also announced positive phase 3 trial results for its drug yesterday. However, the company is still behind its competitor Sanofi SA (SNY), which intends to use a Priority Review Voucher for its own ...
FDA Approves Sanofi's Breakthrough Gaucher Disease Drug
Sanofi's new drug will be a breakthrough, changing the way the disease is treated. Cerdelga, also known as eliglustat, is the first oral treatment, and is designed as a pill.
Related articles »  
Sanofi SA (ADR) (NYSE:SNY) Gets Clearance From The Competition ...
Sanofi SA (ADR) (NYSE:SNY) would acquire 20% stake in Apollo Sugar Clinics Ltd (ASCL) under this deal. Other than the 20% stake, SNY will also get certain management rights in ASCL, which is a subsidiary company of Apollo Health and Lifestyle.
Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza ...
On to other details of the agreement, Sanofi SA (ADR) (NYSE:SNY) and MannKind said in a statement that their agreement involves Sanofi taking over the responsibilities for global commerce, development activities and regulatory matters.
Trader's Watch List �Sanofi SA (ADR) (NYSE:SNY), CenterPoint Energy, Inc ...
Manhattan, NY- Sep 02, 2014 - (Techsonian) - Sanofi SA (ADR) (SNY) recently reported that detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.
FDA Approves Genzyme's Lumizyme For All Ages
Genzyme, a subsidiary of Sanofi SA (ADR) (SNY), announced last Friday, the US Food & Drug Administration's (FDA) approval of Lumizyme (Alglucosidase Alfa) for treating all patients suffering from infantile-onset Pompe disease, including those under the ...
Related articles »  
Pfizer Inc. (NYSE:PFE) May See Lawsuit as Sanofi SA (NYSE:SNY ...
Sanofi Pasteur, the vaccines division of Sanofi SA (ADR) (NYSE:SNY) [Trend Analysis] reported that The New England Journal of Medicine published optimistic results from a large-scale, multi-center efficacy trial, which found that Fluzone High-Dose ...
Related articles »